doi: 10.2337/diabetes.53.1.5 49 WangXZhouJDoyleMEEganJM
By activating glucagon-like peptide-1 (GLP-1) receptors, retatrutide stimulates insulin secretion and inhibits glucagon release, leading to improved blood sugar control
Conflating failed pharmacology with failed biology risks permanently sidelining therapeutically valuable systems, while indiscriminately resurrecting abandoned targets without rigorous criteria risks repeating historical mistakes
Retatrutide isn't yet approved: As of this writing, retatrutide has not received FDA approval
Ideally, patients should receive the dose of a medication that is most effective and best tolerated and this dose may not be one of the fixed doses that are available in a single-dose pen, Kushner says
Despite their promise, GLP-1 drugs need to be treated with caution